

CUTTER



CUTTER BIOLOGICAL
DIVISION OF CUTTER LABORATORIES INC
4TH AND PARKER STREETS
POST OFFICE BOX 1988
BERKELEY, CALIFORNIA 94701
(415) 425-4000

March 3, 1983

Mr. Froitzheim
TROPON WERKE
Berliner Str.
P.O. 80 10 60
5 Koeln 80
West Germany

Dear Mr. Froitzheim:

During Dr. Karl Fischer's recent discussions with Prof. Scharrer at Frankfurt he was asked about Cutter's position on Acquired Immune Deficiency Syndrome (AIDS) and our actions to keep Cutter Koate^R free of this agent. Dr. Fischer has requested that I provide you with information on our procedures so that you may respond to Prof. Scharrer.

A summary of our special precautions to exclude "high risk" donors from donating at any collection facilities supplying plasma to Cutter for use in coagulation products as well as copies of specific procedures used at these centers, are enclosed. Procedures pertinent to AIDS are underlined in red.

Please transmit this information to Prof. Scharrer at your earliest convenience.

Sincerely,

GRO-C

GRO-C

John H. Hink, Director
Plasma Manufacturing
Technology and Procurement

JHH:gml
Encl.

cc: Dr. K. Fischer
B. Modersbach
J. Wood/W. Ewald

701343

Cutter AIDS Action Plan to Reduce "High Risk" Plasma
Donations From Use in the Manufacture of Koate^R

1. No plasma to be used in the manufacture of Cutter coagulation products will be collected in the cities of New York, NY; San Francisco, CA; Los Angeles, CA; or Miami, FL.
2. No plasma collection for use in coagulation products will be carried out in prisons.
- *3. All personnel involved with the screening of plasma donors will be trained in the meaning and use of procedures to screen and reject "high risk" donors at plasma collection facilities supplying plasma for use in Cutter coagulation products.
 - a. donors exhibiting unexplained weight loss must be examined and approved by the Center Medical Director before donation.
 - b. donors having persistent diarrhea, or night sweats.
 - c. male homosexuals.
 - d. residents of, or visitors to Haiti within the past 5 years.
 - e. intravenous drug users

} will not be accepted as donors
- *4. Physicians will conduct skin examination (especially lower limbs) for lesions and lymphadenopathy during regular and special donor examination.
5. A pilot screening program will be conducted at the Cutter Special Testing Laboratory to determine the incidence of hepatitis core antibody positive donors by center and geographical region. Anti-HBc positive donor plasma will be measured for IgG content and samples will be collected for T-cell ratio analysis.

*See attached procedures and forms for detailed information.

John H. Hink, Director
Plasma Manufacturing
Technology and Procurement

201344